Perrigo Company plc Stock Repurchase Program, Authorized Amount
Perrigo Company plc (PRGO) had Stock Repurchase Program, Authorized Amount of $1.00 billion as of 2018-10-31, per its 10-Q filed 2024-05-07.
Discontinued › Notes › Equity
us-gaap:StockRepurchaseProgramAuthorizedAmount1 · last filed 2024-05-07
- 2018-10-31: Stock Repurchase Program, Authorized Amount $1.00B.
- 2017-07-01: Stock Repurchase Program, Authorized Amount $800.00K.
- 2016-10-01: Stock Repurchase Program, Authorized Amount $0.00.
- 2016-07-02: Stock Repurchase Program, Authorized Amount $0.00.
| Period end | Stock Repurchase Program, Authorized Amount |
|---|---|
| 2018-10-31 | $1.00B 10-Q · filed 2024-05-07 |
| 2017-07-01 | $800.00K 10-Q · filed 2017-08-10 |
| 2016-10-01 | $0.00 10-Q · filed 2016-11-10 |
| 2016-07-02 | $0.00 10-Q/A · filed 2017-05-22 |
| 2015-12-31 | $3.30M 10-K · filed 2017-05-22 |
| 2015-10-30 | $2.00B 10-K · filed 2022-03-01 |
| 2015-10-22 | $2.00B 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |